Cullinan Therapeutics, Inc. Overview
Pro stress-test →Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer in the United States. The company believes in a future where people living with autoimmune diseases and cancer spend less time managing their conditions, with a clinical-stage pipeline reflecting a deliberate approach of advancing only the most promising molecules to address high unmet needs.
Strategic Profile
Pro stress-test →The company is committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline. Strategic partnerships include collaboration with Adimab, LLC for antibody discovery and optimization, and a co-development agreement with Taiho Pharmaceutical Co., Ltd for zipalertinib.
Competitive Landscape
Pro stress-test →Primary competitors include ORIC Pharmaceuticals, Aura Biosciences, Sorrento Therapeutics, Xenetic Bioscience, and Arcus Biosciences. Cullinan differentiates through its dual focus on autoimmune diseases and oncology using modality-diverse platforms including T cell engagers, small molecules, and monoclonal antibodies.
Industry Context
Cullinan Therapeutics, Inc. operates in Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics.
Key facts
Founded: 2016 · Headquarters: Cambridge, Massachusetts · Market cap: $820M